Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension
The KARDIA-2 study met its primary endpoint demonstrating additive, placebo-adjusted systolic blood pressure reductions of up to 12.1 mmHgat month three. These results were statistically significant and clinically meaningfulZilebesiran demonstrated an encouraging safety and tolerability profile when added to standard of care antihypertensives Basel, 7 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam today released detailed results from the Phase II KARDIA-2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care (SOC) antihypertensives. T...
Source: Roche Investor Update - April 7, 2024 Category: Pharmaceuticals Source Type: news
Acute high-output heart failure with pulmonary hypertension and severe liver injury caused by amlodipine poisoning: a case report - Wang C, Zhu Q, Tan D, Walline J, Wang Y.
We report a 52-year-old woman who suffered from severe shock after an overdose of amlodipine. Hemodynamic monitoring showed tha... (Source: SafetyLit)
Source: SafetyLit - March 28, 2024 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month threeZilebesiran added to a standard of care hypertension medication demonstrated an encouraging safety and tolerability profile in adults with mild to moderate uncontrolled hypertension, and results support the potential for twice-yearly dosingRoche and Alnylam have initiated the Phase II KARDIA-3 study in adults with uncontrolled hypertension at high cardiovascular riskKARDIA-2 study results will be presented as a late-breaking abstract in April at the 2024 American College of Ca...
Source: Roche Investor Update - March 5, 2024 Category: Pharmaceuticals Source Type: news
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month threeZilebesiran added to a standard of care hypertension medication demonstrated an encouraging safety and tolerability profile in adults with mild to moderate uncontrolled hypertension, and results support the potential for twice-yearly dosingRoche and Alnylam have initiated the Phase II KARDIA-3 study in adults with uncontrolled hypertension at high cardiovascular riskKARDIA-2 study results will be presented as a late-breaking abstract in April at the 2024 American College of Ca...
Source: Roche Media News - March 5, 2024 Category: Pharmaceuticals Source Type: news
Are You Taking Too Many Medications? How to Trim Your Prescription List
Too many seniors are prescribed too many drugs. About four of every 10 older adults take five or more medications, triple the rate from two decades ago. Almost 11 million Americans, or two of every 10 seniors, are on 10 or more drugs.
As a career geriatrician, I’ve seen it firsthand: One of the best ways to improve your personal health is to work with your doctors to edit down your prescription list.
[time-brightcove not-tgx=”true”]
Polypharmacy—when one patient takes multiple drugs—is responsible for a vast but underpublicized American tragedy. Medication overload will contribute to t...
Source: TIME: Health - January 10, 2024 Category: Consumer Health News Authors: Nick Schneeman Tags: Uncategorized freelance healthscienceclimate Source Type: news
Fall risk and cardiovascular outcomes of first-line antihypertensive medications in nursing home residents - Berry SD, Hayes K, Lee Y, Zhang Y, Kim DH, Ko D, Kiel DP, Daielo L, Zhang T, Zullo AR.
BACKGROUND: Little evidence exists about the comparative effects of first-line antihypertensive medications (i.e., renin-angiotensin-aldosterone converting enzyme inhibitors (RAASi), amlodipine, or thiazide diuretics) in older adults with limited life expe... (Source: SafetyLit)
Source: SafetyLit - December 8, 2023 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
Cardiovascular drugs and suicide death: determination of carvedilol, amlodipine, doxazosin and diltiazem in two fatal cases - Santunione AL, Palazzoli F, Verri P, Vandelli D, Castagnetti V, Profeta C, Silingardi E.
A number of medical conditions are identified as risk factors for suicide death; in particular, cardiovascular illnesses are recognized as a major suicide risk factor. In this case, self-poisoning is the common method of suicide and cardiovascular drugs ar... (Source: SafetyLit)
Source: SafetyLit - November 21, 2023 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Amlodipine overdose in a transgender woman: a case study - Bojja S, Javed N, Bojja S, Itare V, Nasr R.
We present a case of a 43-year-old transgender woman who presented ... (Source: SafetyLit)
Source: SafetyLit - September 4, 2023 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
DR ELLIE CANNON: Have blood pressure tablets made me lose my appetite and should I be worried?
DR ELLIE CANNON: Today's reader has noticed that they always feel full since they were put on blood pressure pill, amlodipine, and is asking if they should be concerned? (Source: the Mail online | Health)
Source: the Mail online | Health - April 15, 2023 Category: Consumer Health News Source Type: news
Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news
Accidental paediatric ingestion of amlodipine after pharmacy dispensing error - Shukla A, Rutman M, Moeller J.
We present a case of a paediatric ingestion of amlodipine, res... (Source: SafetyLit)
Source: SafetyLit - August 24, 2022 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news
RPS warns of misleading reports of drug recall
Following reports that blood pressure drugs amlodipine and olmesartan have been recalled, RPS has confirmed that this is not the case in the UK.
It was published online in both the Daily Record and D (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - March 24, 2022 Category: Drugs & Pharmacology Source Type: news
High blood pressure warning: Drug recalled as it may cause ‘adverse health consequences’
TWO blood pressure drugs, amlodipine and olmesartan, that are also available in the UK, have been recalled because of deviations from standard manufacturing protocols. Many hypertension sufferers are prescribed medicines to keep the culprit in check, which consequently reduces the risk of further complications. (Source: Daily Express - Health)
Source: Daily Express - Health - March 19, 2022 Category: Consumer Health News Source Type: news
Katerzia (Amlodipine Oral Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 9, 2022 Category: Drugs & Pharmacology Source Type: news
Norliqva (Amlodipine Oral Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 4, 2022 Category: Drugs & Pharmacology Source Type: news
